Posted Nov. 8, 2013 at 12:12 p.m.

Premium Lock Oxygen Bio nets $6M from warrants, boosts cash position ahead of clinical trials

Published: 2013-11-08 12:12:16
Updated: 2013-11-08 12:12:16

OxyBio OxyBio

With the exercise of those warrants, Oxygen net $6 million giving the Morrisville-based company more cash to apply toward clinical trials for levosimendan, a drug being studied to treat acute decompensated heart failure. Read more about Oxygen's plans....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2015 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders